Switzerland· 65041005
Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml, Injektionslösung
A insulin degludec and liraglutide product containing insulinum degludecum, liraglutidum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Insulin degludec and liraglutide is registered in 12 of 19 countries.
Countries holding a registration under ATC A10AE56 (insulin degludec and liraglutide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Insulin degludec and liraglutide · ATC A10AE56
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- insulinum degludecum, liraglutidum
- Manufacturer
- Novo Nordisk Pharma AG
- Country
- Switzerland (CH)
- ATC code
- A10AE56
- ATC class
- Insulin degludec and liraglutide
- Defined daily dose
- 40 E, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806504100583 Fertpen 3 mlCHF 143.55
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec and liraglutide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXULTOPHYNovo Nordisk A/S, Bagsvaerd
- NorwayXultophyOrifarm AS
- FinlandXultophyNovo Nordisk A/S
- FranceXULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectableNOVO NORDISK (DANEMARK)
- United KingdomXultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- IrelandXultophy 100 units/mL + 3.6 mg/mL solution for injection.Novo Nordisk A/S
- IcelandXultophyNovo Nordisk A/S*
- NetherlandsXultophy 100 eenheden/ml + 3,6 mg/ml oplossing voor injectieNovo Nordisk A.S.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xultophy
- Norway · Xultophy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1a0a042-ace7-4ea2-b68a-3c6ff4aa0688 GET /v1/drugs/b1a0a042-ace7-4ea2-b68a-3c6ff4aa0688?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "insulinum degludecum 100 U + liraglutidum 3.6 mg",
"valid_from": "2014-11-01",
"limitations": "[{\"description\":\"Xultophy wird in Kombination mit Metformin oder mit Metformin plus einem Sulfonylharnstoff zur Behandlung des Typ 2 Diabetes mellitus bei Erwachsenen angewendet, wenn Metformin allein, Metformin in Kombination mit einem Sulfonylharnstoff oder Metformin in Kombination mit einem Basalinsulin keine adäquate Blutzuckerkontrolle gewährleisten.<br>\\nMindestens BMI 28.<br>\\nZusätzliche Medikamente zur Gewichtsreduktion werden nicht vom Krankenversicherer vergütet.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2014-11-01\"}]",
"galenic_form": "Inj Lös 100E/ml 3.6 mg/ml",
"therapeutic_area": null,
"sl_inclusion_date": "2014-11-01",
"self_retention_pct": 10
}See everything about insulin degludec and liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.